Overview

Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia

Status:
Completed

Trial end date:
2019-02-01

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to check if an subcutaneous (sc) infusion of UCB7665 is safe and tolerated in subjects with primary immune thrombocytopenia.

Phase:

Phase 2

Details

Lead Sponsor:

UCB Biopharma S.P.R.L.

Collaborator:

Parexel

Treatments:

Rozanolixizumab